glp-1 and mash BREAKTHROUGH: FDA APPROVES TREATMENT FOR SERIOUS LIVER DISEASE Semaglutide, a medication already known for its role in weight management, is now the first GLP-1 therapy approved to treat (Metabolic Dysfunction–Associated Semaglutide Receives FDA Approval for
Description
J Cardiovasc Dev Dis
DOI: 10.1038/s44360-026-00108-y The authors report no outside funding
Given that our data show that more than half the patients taking GLP-1 medications earn less than $40,000 per year, this presents a financial challenge
This product skirts the line of legitimacy
These tools act as both an early warning system and a verification mechanism for GLP-1 cold chain performance
Pharmacy representatives, however, warned that some of the proposed language could unintentionally restrict legitimate compounding practices and limit patient access to needed medications
